Biden’s COVID Vaccine Push Crashes Into Reality

Politico reported:

Buzzing razors collided with roaring laughter that collectively rose and fell as James Brown screeched in the backdrop. It’s so loud at the “It’s Official Barbershop” that it’s hard to hear the reply from Mark Harmon, a soft-spoken 17-year-old wearing a McDonald’s sweatshirt, when asked if he had gotten the COVID vaccine.

“No,” he said. And there was little that would persuade him. “I don’t know what they’re putting in it … They gotta tell me every ingredient.”

Biden’s Plan to Deploy Federal Teams in Door-to-Door COVID Vaccine Campaign Sparks Backlash

The Defender reported:

President Joe Biden on Tuesday announced plans to ramp up the federal government’s efforts to get more Americans vaccinated against COVID under a new program that includes “literally knocking on doors,” as Biden puts it.

Speaking from the White House two days after the federal government fell short of its goal of having 70% of adults get their first COVID shot by July 4, Biden said:

“So, please get vaccinated now. It works. It’s free. And it’s never been easier, and it’s never been more important. Do it now — for yourself and the people you care about; for your neighborhood; for your country. It sounds corny, but it’s a patriotic thing to do.”

COVID Vaccine-Related Blood Clots Linked to Amino Acids in New Study

The Wall Street Journal reported:

Canadian researchers say they have pinpointed a handful of amino acids targeted by key antibodies in the blood of some people who received AstraZeneca PLC’s COVID-19 vaccine, offering fresh clues to what causes rare blood clots associated with the shot.

The peer-reviewed findings, by a team of researchers from McMaster University in Ontario, were published online Wednesday by the science journal Nature. They could help doctors rapidly test for and treat the unusual clotting, arising from an immune-driven mix of coagulation and loss of platelets that stop bleeding.

Lead Sinovac Vaccine Scientist in Indonesia Dies of Suspected COVID, Media Say

Reuters reported:

The lead scientist on China’s Sinovac vaccine trials in Indonesia died of suspected COVID-19 on Wednesday, Indonesian media said.

The death of Novilia Sjafri Bachtiar comes as fatalities from the coronavirus reach record highs in Indonesia, one of the countries where the Sinovac vaccine has been most widely used.

Pfizer COVID Vaccine Now in Phase-Two Testing at Cincinnati Children’s Hospital

WCPO reported: 

Researchers at Cincinnati Children’s Hospital are starting phase-two testing of Pfizer’s COVID-19 vaccine to help determine the efficacy of the vaccine in children younger than 12 years old.

Phase one of testing helped establish how much of the vaccine is needed by different age groups, and now researchers are working to establish how much immunity from the virus each dose provides.

Researchers will use a process called “immunobridging” to compare the immune response among children to the immune response seen in adults and teenagers.

Should People With Immune Problems Get Third Vaccine Doses?

New York Times via Economic Times reported:

When it came to coronavirus vaccination, the third time was the charm for Esther Jones, a dialysis nurse in rural Oregon. After two doses of the Pfizer-BioNTech vaccine failed to jolt her immune system into producing antibodies, she sought out a third, this time the Moderna shot.

When it came to coronavirus vaccination, the third time was the charm for Esther Jones, a dialysis nurse in rural Oregon. After two doses of the Pfizer-BioNTech vaccine failed to jolt her immune system into producing antibodies, she sought out a third, this time the Moderna shot.

WHO Advises 2 Monoclonal Antibodies for Severe COVID

CIDRAP reported:

The World Health Organization (WHO) today recommended the use of anti-inflammatory monoclonal antibodies—tocilizumab and sarilumab—alongside corticosteroids for treating patients who have severe or critical COVID-19 infections.

The WHO’s treatment recommendation comes in the wake of a study published today in the Journal of the American Medical Association (JAMA), in which researchers analyzed 27 randomized trials that involved nearly 11,000 patients. They found that the interleukin-6 antagonists tocilizumab and sarilumab reduced the risk of death and the need for mechanical ventilation.

WHO Recommends Roche, Sanofi Drugs for COVID to Cut Death Risk

Reuters reported:

The World Health Organization on Tuesday recommended using arthritis drugs Actemra from Roche (ROG.S) and Kevzara from Sanofi (SASY.PA) with corticosteroids for COVID-19 patients after data from some 11,000 patients showed they cut the risk of death.

A WHO group evaluating therapies concluded treating severe and critical COVID patients with these so-called interleukin-6 antagonists that block inflammation “reduces the risk of death and the need for mechanical ventilation.”

COVID Drug Recommended By WHO Remains Unaffordable and Inaccessible for Most People

Doctors Without Borders reported:

As the World Health Organization (WHO) recommended today the drug tocilizumab for people with severe COVID-19, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) called on the Swiss pharmaceutical corporation Roche—the world’s sole producer of the drug—to lower the price and make it accessible for everyone who needs it. Additionally, Roche must end its monopoly and urgently share the know-how, technology, and additional information necessary for other manufacturers across the world to produce the medicine as well, which would ensure adequate supply and access for people everywhere, said MSF.

Dr. Scott Gottlieb Says People Who Had COVID Get ‘Best of Both Worlds’ if They Get Vaccinated

CNBC reported:

Dr. Scott Gottlieb believes people who have previously been infected with the coronavirus would still benefit from receiving COVID vaccines.

In Tuesday’s interview on CNBC’s “Squawk Box,” the former Food and Drug Administration commissioner acknowledged that some individuals may think that antibodies generated from having the disease offer enough protection against future infection or illness and, as a result, forgo getting a COVID inoculation. The reason to still receive a vaccine is “twofold,” contended Gottlieb, who serves on the board of vaccine maker Pfizer.

Is Moderna’s Vaccine Breakthrough Really Worth $100 Billion?

Financial Advisor reported:

Just 18 months ago, Moderna Inc. was an early-stage biotechnology company working on a new way of making vaccines worth $6.5 billion. Today, after it developed and delivered one of the fastest-arriving and most effective shots against COVID-19, Moderna’s market value is approaching $100 billion.

The post Biden’s COVID Vaccine Push Crashes Into Reality + More appeared first on Children’s Health Defense.